Mostrar el registro sencillo del ítem

dc.contributor.authorQuiñones Vico, María Isabel 
dc.contributor.authorFernández González, Ana
dc.contributor.authorPérez Castejón, Elena
dc.contributor.authorMontero Vílchez, Trinidad
dc.contributor.authorArias Santiago, Salvador Antonio 
dc.date.accessioned2021-03-25T11:52:50Z
dc.date.available2021-03-25T11:52:50Z
dc.date.issued2021-02-08
dc.identifier.citationQuiñones-Vico, M.I.; Fernández-González, A.; Pérez-Castejón, E.; Montero-Vílchez, T.; Arias-Santiago, S. Cytotoxicity and Epidermal Barrier Function Evaluation of Common Antiseptics for Clinical Use in an Artificial Autologous Skin Model. J. Clin. Med. 2021, 10, 642. [https://doi.org/10.3390/jcm10040642]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/67715
dc.description.abstractBioengineered artificial skin substitutes (BASS) are the main treatment used in addition to autografts when skin injuries involve a large body surface area. Antiseptic/antibiotic treatment is necessary to prevent infections in the BASS implant area. This study aims to evaluate the effect of antiseptics and antibiotics on cell viability, structural integrity, and epidermal barrier function in BASS based on hyaluronic acid during a 28 day follow-up period. Keratinocytes (KTs) and dermal fibroblasts (DFs) were isolated from skin samples and used to establish BASS. The following antibiotic/antiseptic treatment was applied every 48 h: colistin (1%), chlorhexidine digluconate (1%), sodium chloride (0.02%), and polyhexanide (0.1%). Cell viability (LIVE/DEAD® assay), structural integrity (histological evaluation), and epidermal barrier function (trans-epidermal water loss, (TEWL), Tewameter®) were also evaluated. Cell viability percentage of BASS treated with chlorhexidine digluconate was significantly lower (p 0.001) than the other antiseptics at day 28. Compared to other treatments, chlorhexidine digluconate and polyhexanide significantly affected the epithelium. No significant differences were found regarding epidermal barrier. These results may be useful for treatment protocols after implantation of BASS in patients and evaluating them in clinical practice. BASS represent a suitable model to test in vitro the impact of different treatments of other skin wounds.es_ES
dc.description.sponsorshipMinistry of Science, Innovation and Universities of Spaines_ES
dc.description.sponsorshipUniversity of Granadaes_ES
dc.description.sponsorshipInstituto de Salud Carlos III PI13/02576 PI17/02083es_ES
dc.description.sponsorshipEuropean Regional Development Fund "A way to make Europe"es_ES
dc.description.sponsorshipAndalusian Regional Government SAS PI-0458-2016es_ES
dc.language.isoenges_ES
dc.publisherMdpies_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectAntiseptic/antibiotic testinges_ES
dc.subjectBioengineered artificial skin substitutees_ES
dc.subjectCell viabilityes_ES
dc.subjectEpidermal barrier functiones_ES
dc.subjectRegenerative medicinees_ES
dc.subjectWound healinges_ES
dc.titleCytotoxicity and Epidermal Barrier Function Evaluation of Common Antiseptics for Clinical Use in an Artificial Autologous Skin Modeles_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3390/jcm10040642
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 3.0 España